Description: Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.
Home Page: devyser.com
InstrumentvAegen 19
Hägersten,
126 53
Sweden
Phone:
46 8 56 21 58 50
Officers
| Name | Title |
|---|---|
| Mr. Fredrik Alpsten | Chief Executive Officer |
| Ms. Sabina Berlin | Chief Financial Officer |
| Mr. Michael Uhlin Ph.D. | Chief Scientific Officer |
| Ms. Camilla Wiberg | Chief Human Resource Officer |
| Mr. Theis Kipling | Chief Commercial Officer |
| Mr. John Murad | VP & GM of Devyser US |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 34.7222 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8676 |
| Price-to-Sales TTM: | 10.3343 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 119 |